Life Science Nation Newsletter | April 11, 2019 | Issue 312

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
   Life Science Investor Mandates
(Apr. 4 - Apr. 10 )
Makes Seed Investments in Companies Addressing Alzheimer's Disease and Clinical Trial/Basic Research Tools
Invests Up to $30M in Therapeutics, with Strong Preference for Orphan & Rare Diseases
Invests in High Growth Opportunities in Medical Devices, Diagnostics, and Digital Health Sectors
Invests in Early to Mid-Stage Repurposed/Reposition Drugs, Especially in CNS and Respiratory Disease
LSN Services
LSN Videos
LSN Media Partners
By Lucy Parkinson, VP of Investor Research, LSN

Life Science Nation (LSN) is looking ahead to our Philadelphia event on June 3rd. With many investors from LSN's network coming to the Mid-Atlantic region for the international conference week, and many others based locally, RESI has already attracted a flurry of investor registrants. We are expecting a total of over 300 investors at the event. Below, you can check out those who are already committed.

The end of RESI Philadelphia's Early Bird period is approaching next week - if you're interested in networking with the hundreds of investors who will be attending, you have til April 19th to take advantage of the Early Bird opportunity...

By Karen Deyo, Investor Research Analyst, LSN

Securing a partnership with a Big Pharma is widely considered as the Holy Grail for therapeutics startups. However, companies need to consider: is this the best path forward? What does the partnership entail and how do you go about getting there? Can companies outside of therapeutics partner with a Big Pharma? At RESI Europe on March 25th in Vienna, the Big Pharma panel addressed these questions, and more.

The panel first addressed the biggest question: should a company seek out a Big Pharma partnership? The panelists stressed the need to have a strategy in place before approaching a Big Pharma. It isn't enough to want a partnership - the company needs to have a plan in mind for what form this partnership will take. Partnerships between startups and Big Pharma can take many forms, including support for animal or pharmacology studies to which the company doesn't have access, clinical trial or manufacturing and optimization assistance. All of this can come in the form of in-kind partnerships, MTAs or partnerships with milestone payments, so a clear plan for the collaboration needs to be in place before approaching a Big Pharma. That being said, it is important to be flexible, as the deal may not end up as you had originally planned...

By George Kamphaus, Business Development Representative, LSN

Life Science Nation and the Redefining Early Stage Investments (RESI) conference always bring together a truly global group of attendees. On March 25th, at RESI Europe in Vienna, the investors, channel partners and entrepreneurs present represented 31 countries, and 5 different continents. When LSN says that we have a global ecosystem, it's not hyperbole! The Innovation Challenge finalists were equally diverse, with the presenting companies coming from 13 different countries (including Argentina - the first finalist from South America) and 5 states in the US.

The companies attending RESI, 35% of registered attendees, represented all of the silos, including therapeutics, diagnostics, medical devices and digital health, with some companies representing multiple sectors. As with all RESI conferences, the investor-to-startup ratio was 1:1, with investors as 36% of the attendees...

Created & Produced by